Advances in HPLC technology for the determination of drug impurities

Olsen, Bernard A.; Castle, Bryan C.; Myers, David P.

doi:10.1016/j.trac.2006.06.005

Cited by 46 publications

(24 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But even if this is overcome, microparticulate packed columns can be damaged by the excessive pressure associated to high flow rates [5]. Diverse approaches have been considered to face this limitation: use of microparticulate short columns at high flow rate [6 -8], special packings with reduced retention [9], high temperature [10], reduced particle size at ultra-high pressure [11] and silica-based monolithic columns [12,13]. With shorter microparticulate columns, efficiency and resolution are considerably compromised, and high temperatures or ultra-high pressures require special chromatographic equipment.…”

Section: Introductionmentioning

confidence: 99%

Performance of a Chromolith RP‐18e column for the screening of β‐blockers

Pous-Torres

Ruiz-Ángel

Torres-Lapası́o

et al. 2009

J of Separation Science

View full text Add to dashboard Cite

The chromatographic performance of a monolithic column (Chromolith RP-18e) was comprehensively examined in the isocratic separation of ten beta-blockers, using ACN-water mobile phases, and compared with the performance of three microparticulate RP columns manufactured with different types of silica: Spherisorb ODS-2, Kromasil C18 and XTerra MS C18. The comparison considered the analysis time, selectivity, peak shape (column efficiency and asymmetry) and resolution, and was extended to a wide range of mobile phase compositions. The Chromolith column showed good performance for the analysis of beta-blockers with regard to the packed columns. In terms of selectivity and analysis time, the greatest similarity was found between the Chromolith and XTerra columns. The addition of a silanol blocking agent (0.1% triethylamine) to both Chromolith and Spherisorb columns yielded, apparently, a similar blocking degree of the silanol groups (based on the similar peak shapes), and gave rise to similar selectivity.

show abstract

Section: Introductionmentioning

confidence: 99%

Performance of a Chromolith RP‐18e column for the screening of β‐blockers

Pous-Torres

Ruiz-Ángel

Torres-Lapası́o

et al. 2009

J of Separation Science

View full text Add to dashboard Cite

show abstract

“…Key players in the global API market include Teva Pharmaceutical Industries Ltd., and Zhejiang NHU Co., Ltd, Zhejiang Medicine Co. North China Pharmaceutical Group Corp. (NCPC) and Northeast Pharmaceutical Group Co, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma, Sandoz (Novartis AG), Zhejiang Huahai Pharmaceutical Co.,Ltd, Ltd and Zhejiang Hisun Pharmaceutical Co., Ltd [11][12][13][14][15].…”

Section: Mini Reviewmentioning

confidence: 99%

Impurity: Pharma Market and Importance

Kulkarni¹

2017

MOJBOC

View full text Add to dashboard Cite

“…Several reviews have been published on the developments in HPLC technology for drug impurity profiling and other drug-related issues, e.g., Ref. [28].…”

Section: High-performance Liquid Chromatographymentioning

confidence: 99%

The paradigm shifting role of chromatographic methods in pharmaceutical analysis

Gǒrög

2012

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

Advances in HPLC technology for the determination of drug impurities

Cited by 46 publications

References 40 publications

Performance of a Chromolith RP‐18e column for the screening of β‐blockers

Performance of a Chromolith RP‐18e column for the screening of β‐blockers

Impurity: Pharma Market and Importance

The paradigm shifting role of chromatographic methods in pharmaceutical analysis

Contact Info

Product

Resources

About